|
Comprehensive analysis of germline and somatic BRCA1/2 mutations in ovarian cancer population: Interim results of OVATAR prospective study. |
|
|
Speakers' Bureau - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - BioSyntech; ICBFM |
Travel, Accommodations, Expenses - Kedrion Biopharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Eisai; Merck Serono; Novartis; Pfizer; Roche; Sanofi |
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Eisai; Merck Serono; Novartis; Pfizer; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Abbott |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche |
Research Funding - AstraZeneca; Novartis; Sanofi |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Speakers' Bureau - AstraZeneca; Teva |
Research Funding - AstraZeneca; Teva |
Travel, Accommodations, Expenses - Eisai; MSD |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - RosPharmTech |
Speakers' Bureau - AstraZeneca; Lilly; Sanofi |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche |